https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261009 BiopharmaWatch en 2026-10-09T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/CCEL/cryo-cell-reports-fiscal-q3-2026-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVH/evolent-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grant-nyse-american BiopharmaWatch en 2026-10-09T20:15:29.000Z AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-1-15-billion-offerings BiopharmaWatch en 2026-10-09T20:05:09.000Z Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes https://www.biopharmawatch.com/news/ACH/accendra-health-nyse-listing-standard-notice BiopharmaWatch en 2026-10-09T20:05:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-09T20:05:00.000Z Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ASTH/astrana-health-q3-financial-results-2026 BiopharmaWatch en 2026-10-09T20:05:00.000Z Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/AGEN/agenus-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-09T19:23:00.000Z Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference https://www.biopharmawatch.com/news/VRTX/vertex-alytfrek-data-north-american-cystic-fibrosis-conference BiopharmaWatch en 2026-10-09T17:15:00.000Z Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/BIAF/wallachbeth-capital-announces-closing-bioaffinity-technologies-4-million-registered-direct BiopharmaWatch en 2026-10-09T16:30:00.000Z WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-thinkequity-conference-2026 BiopharmaWatch en 2026-10-09T16:05:00.000Z Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-inc-announces-closing-4-million-registered-direct-financing BiopharmaWatch en 2026-10-09T15:37:00.000Z bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BMRN/biomarin-advances-achondroplasia-hypochondroplasia-treatment BiopharmaWatch en 2026-10-09T13:05:00.000Z BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting https://www.biopharmawatch.com/news/HCWB/hcw-biologics-ind-application-solid-tumors BiopharmaWatch en 2026-10-09T13:00:00.000Z HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-aha-hypertension-sessions-2026 BiopharmaWatch en 2026-10-09T13:00:00.000Z Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 https://www.biopharmawatch.com/news/CLGN/collplant-announces-private-placement-3-7-million BiopharmaWatch en 2026-10-09T13:00:00.000Z COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT https://www.biopharmawatch.com/news/RPRX/royalty-pharma-third-quarter-2026-results BiopharmaWatch en 2026-10-09T12:53:25.000Z Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-greg-dipasquale-cco BiopharmaWatch en 2026-10-09T12:30:00.000Z Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer https://www.biopharmawatch.com/news/ARQT/arcutis-zoryve-data-eadv-fall-clinical BiopharmaWatch en 2026-10-09T12:00:27.000Z Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q3-2026-earnings-release BiopharmaWatch en 2026-10-09T12:00:00.000Z Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/NTRA/fda-breakthrough-device-natera-multi-cancer-assay BiopharmaWatch en 2026-10-09T12:00:00.000Z FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-cvr-agreement-shareholder-participation BiopharmaWatch en 2026-10-09T12:00:00.000Z Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-revera-301-european-participant BiopharmaWatch en 2026-10-09T12:00:00.000Z Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-acg-ueg-conferences-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-relaunches-irulya-therapeutics BiopharmaWatch en 2026-10-09T12:00:00.000Z Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-09T12:00:00.000Z Filana Therapeutics to Participate in the 2026 Maxim Growth Summit https://www.biopharmawatch.com/news/TLX/profound-telix-co-education-agreement-psma-prostate-care BiopharmaWatch en 2026-10-09T11:45:00.000Z Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care https://www.biopharmawatch.com/news/SBFM/sunshine-biopharma-closes-public-offering-20-million BiopharmaWatch en 2026-10-09T11:17:00.000Z Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-present-canaccord-genuity-drug-device-conference BiopharmaWatch en 2026-10-09T11:05:00.000Z Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-virtual-investor-day-october-2026 BiopharmaWatch en 2026-10-09T11:00:13.000Z X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders https://www.biopharmawatch.com/news/JNJ/johnson-johnson-icotyde-long-term-results-plaque-psoriasis BiopharmaWatch en 2026-10-09T11:00:00.000Z New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis https://www.biopharmawatch.com/news/TEVA/teva-fda-approval-weltruza-olanzapine-injection BiopharmaWatch en 2026-10-09T11:00:00.000Z Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-glyphago-phase-1-data-ecnp-2026 BiopharmaWatch en 2026-10-09T11:00:00.000Z Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress https://www.biopharmawatch.com/news/GKOS/glaukos-phase-4-trial-idose-tr-cataract-surgery BiopharmaWatch en 2026-10-09T11:00:00.000Z Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261009 BiopharmaWatch en 2026-10-09T11:00:00.000Z Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SGMT/sagimet-denifanstat-phase-3-results-dermatology-conference BiopharmaWatch en 2026-10-09T11:00:00.000Z Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference https://www.biopharmawatch.com/news/LLY/new-phase-3b-data-lilly-taltz-zepbound-psoriasis-obesity BiopharmaWatch en 2026-10-09T10:45:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-inducement-grants-new-employees BiopharmaWatch en 2026-10-09T08:42:00.000Z LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VOGX/vogenx-appoints-richard-gorman-cfo BiopharmaWatch en 2026-10-09T08:00:00.000Z Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer https://www.biopharmawatch.com/news/ALMS/alumis-phase-3-envudeucitinib-psoriasis-data BiopharmaWatch en 2026-10-09T08:00:00.000Z Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-needle-free-radiation-preparedness BiopharmaWatch en 2026-10-09T07:45:00.000Z Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers https://www.biopharmawatch.com/news/PHVS/deucrictibant-phase-3-study-results-hai-attack BiopharmaWatch en 2026-10-08T22:35:00.000Z Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet https://www.biopharmawatch.com/news/CVS/aetna-2027-star-ratings-clinical-quality-member-experience BiopharmaWatch en 2026-10-08T22:03:00.000Z Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-cms-2027-star-ratings BiopharmaWatch en 2026-10-08T21:00:00.000Z Alignment Healthcare Earns 4 Stars or Higher for Six of Seven Eligible Medicare Advantage Contracts in CMS 2027 Star Ratings https://www.biopharmawatch.com/news/AGEN/armenian-authorization-agenus-bot-bal-mcrc BiopharmaWatch en 2026-10-08T20:41:00.000Z Riassunto: L’Armenia concede le prime autorizzazioni alla commercializzazione di Agenus BOT+BAL per la terapia del carcinoma colorettale metastatico MSS già trattato https://www.biopharmawatch.com/news/AGEN/armenian-approval-for-agenus-bot-bal-mcrc BiopharmaWatch en 2026-10-08T20:41:00.000Z Samenvatting: Armenië verleent eerste vergunningen om Agenus’ BOT+BAL ten behoeve van eerder behandeld MSS gemetastaseerd colorectaal carcinoom in de handel te brengen https://www.biopharmawatch.com/news/AGEN/armenien-marktzulassungen-bot-bal-agenus BiopharmaWatch en 2026-10-08T20:40:00.000Z Armenien erteilt erste Marktzulassungen für BOT+BAL von Agenus bei zuvor behandeltem MSS-metastasiertem Kolorektalkarzinom https://www.biopharmawatch.com/news/SION/sionna-therapeutics-nacfc-2026-data-presentation BiopharmaWatch en 2026-10-08T20:30:07.000Z Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/CON/concentra-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-08T20:30:00.000Z Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/ZTS/zoetis-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-08T20:15:00.000Z Zoetis Declares Fourth Quarter 2026 Dividend https://www.biopharmawatch.com/news/BDX/bd-announces-financial-results-q4-fiscal-2026 BiopharmaWatch en 2026-10-08T20:15:00.000Z BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026 https://www.biopharmawatch.com/news/BKD/brookdale-reports-september-2026-occupancy BiopharmaWatch en 2026-10-08T20:15:00.000Z Brookdale Reports September 2026 Occupancy https://www.biopharmawatch.com/news/GH/guardant-health-guardant360-cdx-approval-europe BiopharmaWatch en 2026-10-08T20:12:00.000Z Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-autonomous-lab-nsf-x-labs BiopharmaWatch en 2026-10-08T20:10:00.000Z Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program https://www.biopharmawatch.com/news/ILMN/illumina-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-08T20:06:00.000Z Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/AGMB/agomab-ontunisertib-ueg-week-2026 BiopharmaWatch en 2026-10-08T20:05:08.000Z Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation https://www.biopharmawatch.com/news/OCS/oculis-publishes-notifications-transactions-persons-discharging-managerial-20261008 BiopharmaWatch en 2026-10-08T20:05:07.000Z Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-10-08T20:05:00.000Z Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-givastomig-esmo-2026 BiopharmaWatch en 2026-10-08T20:05:00.000Z NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026 https://www.biopharmawatch.com/news/ABCL/abcellera-phase-1-2-data-abcl635-tms-2026 BiopharmaWatch en 2026-10-08T20:05:00.000Z AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-mps-iiib-data-presentation BiopharmaWatch en 2026-10-08T20:05:00.000Z Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting https://www.biopharmawatch.com/news/GH/guardant-health-third-quarter-2026-results BiopharmaWatch en 2026-10-08T20:05:00.000Z Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LKFT/lakefront-transparantieverklaring-bank-of-america BiopharmaWatch en 2026-10-08T20:01:00.000Z Lakefront ontvangt transparantieverklaring van Bank of America https://www.biopharmawatch.com/news/LKFT/lakefront-receives-transparency-notification-bank-america BiopharmaWatch en 2026-10-08T20:01:00.000Z Lakefront Receives Transparency Notification from Bank of America https://www.biopharmawatch.com/news/HIT/health-in-tech-launches-hitrx-broker-first-environment BiopharmaWatch en 2026-10-08T20:00:00.000Z Health In Tech Launches HitRix, a Broker-First Environment for Self-Funded Stop-Loss Placement https://www.biopharmawatch.com/news/STAA/staaar-surgical-names-andrew-pilon-vp-business-development BiopharmaWatch en 2026-10-08T19:14:00.000Z STAAR Surgical Names Andrew Pilon as Vice President of Business Development https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-4-million-financing BiopharmaWatch en 2026-10-08T17:30:00.000Z WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-financing-common-stock BiopharmaWatch en 2026-10-08T16:07:00.000Z bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-laboratory-ute-tribe BiopharmaWatch en 2026-10-08T13:26:00.000Z Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-12-million-offering BiopharmaWatch en 2026-10-08T13:22:00.000Z China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-application-ameluz-actinic-keratoses BiopharmaWatch en 2026-10-08T13:22:00.000Z Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body https://www.biopharmawatch.com/news/DARE/dare-bioscience-phase-1-sildenafil-cream-data-smsna BiopharmaWatch en 2026-10-08T13:15:00.000Z Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting https://www.biopharmawatch.com/news/ILMN/illumina-releases-spliceai2-advance-rare-disease-research BiopharmaWatch en 2026-10-08T13:15:00.000Z Illumina releases SpliceAI2 to help advance rare disease research https://www.biopharmawatch.com/news/PHG/philips-global-clinical-advisory-board-oral-care BiopharmaWatch en 2026-10-08T13:00:00.000Z Philips Oral Healthcare Establishes Global Clinical Advisory Board to Help Shape the Future of Oral Care Through Scientific and Clinical Insight https://www.biopharmawatch.com/news/MYGN/sophia-genetics-myriad-genetics-collaboration-prgis BiopharmaWatch en 2026-10-08T13:00:00.000Z SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-financial-restructuring-capital-improvements BiopharmaWatch en 2026-10-08T13:00:00.000Z ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements https://www.biopharmawatch.com/news/IMNN/imunon-participate-investor-conferences-october-2026 BiopharmaWatch en 2026-10-08T13:00:00.000Z IMUNON to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MYGN/myriad-genetics-sophia-genetics-collaboration-prostate-cancer BiopharmaWatch en 2026-10-08T13:00:00.000Z Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology https://www.biopharmawatch.com/news/PRVA/privia-health-third-quarter-2026-results BiopharmaWatch en 2026-10-08T13:00:00.000Z Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 https://www.biopharmawatch.com/news/FEMY/femasys-asrm-2026-exhibit BiopharmaWatch en 2026-10-08T13:00:00.000Z Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo https://www.biopharmawatch.com/news/NAGE/restore-niagen-longevity-month-october BiopharmaWatch en 2026-10-08T12:57:00.000Z Restore Hyper Wellness® and Niagen Bioscience Team Up to Help Americans Age Better This October https://www.biopharmawatch.com/news/NAGE/andrew-shao-awarded-annette-dickinson-trailblazer-award BiopharmaWatch en 2026-10-08T12:32:00.000Z Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) https://www.biopharmawatch.com/news/IBRX/immunitybio-participate-piper-sandler-oncology-symposium BiopharmaWatch en 2026-10-08T12:30:00.000Z ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium https://www.biopharmawatch.com/news/VIR/vir-biotechnology-fda-fast-track-vir-5500 BiopharmaWatch en 2026-10-08T12:30:00.000Z Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-presents-late-breaking-data-aha-2026 BiopharmaWatch en 2026-10-08T12:30:00.000Z CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 https://www.biopharmawatch.com/news/NXL/nexalin-technology-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-10-08T12:30:00.000Z Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing https://www.biopharmawatch.com/news/BFLY/butterfly-network-q3-2026-financial-results BiopharmaWatch en 2026-10-08T12:05:00.000Z Butterfly Network to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/MDCX/medicus-pharma-three-years-progress-long-term-value BiopharmaWatch en 2026-10-08T12:00:19.000Z Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value https://www.biopharmawatch.com/news/BHST/tate-lyle-bioharvest-sweetener-milestone BiopharmaWatch en 2026-10-08T12:00:00.000Z Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme https://www.biopharmawatch.com/news/SRRK/scholar-rock-resubmits-apitegromab-maa-ema BiopharmaWatch en 2026-10-08T12:00:00.000Z Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-japanese-patent-allowance BiopharmaWatch en 2026-10-08T12:00:00.000Z bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm https://www.biopharmawatch.com/news/INCY/incyte-third-quarter-financial-results BiopharmaWatch en 2026-10-08T12:00:00.000Z Incyte to Report Third Quarter Financial Results https://www.biopharmawatch.com/news/LTRN/lantern-pharma-thinkequity-conference-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026 https://www.biopharmawatch.com/news/LUCY/innovative-eyewear-launches-lucyd-aero-smart-glasses BiopharmaWatch en 2026-10-08T12:00:00.000Z Innovative Eyewear, Inc. Launches Lucyd Aero https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-equinox-hfpef-trial-edg-15400 BiopharmaWatch en 2026-10-08T12:00:00.000Z Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 https://www.biopharmawatch.com/news/TECH/bio-techne-expands-gmp-manufacturing-bristol-facility BiopharmaWatch en 2026-10-08T12:00:00.000Z Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-certespetide-pancreatic-cancer-patent BiopharmaWatch en 2026-10-08T12:00:00.000Z Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors https://www.biopharmawatch.com/news/XAIR/beyond-air-preannounces-revenue-q3-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-08T12:00:00.000Z Enovis to Host Third Quarter 2026 Results Conference Call on November 5th https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-acg-2026-voquezna-data BiopharmaWatch en 2026-10-08T12:00:00.000Z Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/ENTX/entera-bio-eb613-phase-3-study-asbmr-2026 BiopharmaWatch en 2026-10-08T12:00:00.000Z Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/AMRX/amneal-third-quarter-2026-results BiopharmaWatch en 2026-10-08T12:00:00.000Z Amneal to Report Third Quarter 2026 Results on November 3, 2026 https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-appoints-david-zhang BiopharmaWatch en 2026-10-08T12:00:00.000Z Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors